KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

TSVT announced that it will discontinue enrollment in its ongoing phase III KarMMa-9 study.The study is evaluating Abecma ...

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...

Shares of 2seventy bio (NASDAQ:TSVT) lost ~16% in the premarket Wednesday after the cancer drug developer and its partner ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

(Endpoints News) Bristol Myers Squibb and 2seventy bio announced discontinuation of enrollment in the phase III KarMMa-9 ...

The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.

Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...

Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.

Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target remains the same with $37.00. Terence Flynn has ...